Abstract
Background and Aims
Programmed death-ligand 1 (PD-L1) is an immune checkpoint molecule with proven therapeutic and prognostic implications. However, its prognostic significance in skin neoplasms remains controversial. In this study, we aimed to evaluate the prognostic value of PD-L1 expression in skin neoplasms.
Methods
We systematically searched PubMed, Scopus, and Web of Science databases up to March 2025, to evaluate overall survival (OS) and disease-free survival (DFS) as outcome measures. Subgroup analyses were performed based on tumor type. Heterogeneity and publication bias were assessed using I² statistics and funnel plots, respectively.
Results
A total of 24 studies were included. In the meta-analysis of OS on 12 studies, PD-L1 expression was not significantly associated with survival [HR = 0.89, 95% CI: 0.70-1.12]. However, subgroup analysis showed that PD-L1 expression was associated with improved OS in Merkel cell carcinoma [HR = 0.39, 95% CI: 0.18-0.83]. For DFS (8 studies), PD-L1 expression showed no significant overall association [random-effects HR = 0.86, 95% CI: 0.54-1.38], but it predicted better DFS in melanoma and cutaneous squamous cell carcinoma, and worse DFS in cutaneous angiosarcoma and sebaceous gland carcinoma. Additionally, in squamous cell carcinoma, PD-L1 expression was significantly associated with the risk of lymph node metastasis [OR = 5.33, 95% CI: 2.21-12.89].
Conclusion
The prognostic significance of PD-L1 expression in skin neoplasms appears to be subtype-specific, correlating with improved survival in some cancers such as Merkel cell carcinoma, but with worse outcomes in others like cutaneous angiosarcoma and sebaceous gland carcinoma.
Get full access to this article
View all access options for this article.